Repurposing a detrimental antibody epitope as targeted therapeutics for sepsis and rheumatoid arthritis

Military Medical Research · Published 2026-02-17 · DOI 10.1186/s40779-026-00686-8

Authors being retrieved — see the publisher record. https://doi.org/10.1186/s40779-026-00686-8

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Virtual medicine: medical AI in human health and diseases · Military Medical Research · 2026 · Same journal
RIMKLA promotes hypertension by activating PKM2 to trigger VSMC phenotype switch · Military Medical Research · 2026 · Same journal
A translational preclinical strategy for chronic spinal cord injury: neuroprotective and regenerative potential of botulinum neurotoxin type A combined with muscle atrophy prevention via electrostimulation · Military Medical Research · 2026 · Same journal
Target trial emulation in oncology: current use and future directions · Military Medical Research · 2026 · Same journal
The national and provincial disease and indirect economic burden of high alcohol use in China from 1990 to 2023 with forecasting to 2050 · Military Medical Research · 2026 · Same journal
Targeting intratumoral bacteria reverses MHC-I suppression and enhances nano-based chemoimmunotherapy in colorectal cancer · Military Medical Research · 2026 · Same journal
Non-invasive evaluation of muscle invasion and survival prognosis in bladder cancer using enhanced CT-based deep learning radiomics: a multi-center real-world cohort study · Military Medical Research · 2026 · Same journal
3D bioprinting of tissues and organs for systemic diseases and localized injuries · Military Medical Research · 2026 · Same journal
Burden of antimicrobial resistance in the WHO Southeast Asia and Western Pacific Regions, 1990–2021: a cross-country systematic analysis with forecasts to 2050 · Military Medical Research · 2026 · Same journal
From RCT to mechanistic study: ATRA reverses myofibroblast activation by reprogramming glucose metabolism via HIC1 and PCK1/2 to attenuate hypertrophic scar formation · Military Medical Research · 2026 · Same journal